News

Themis Receives EMA PRIME Designation for Chikungunya Vaccine

Vienna (Austria), 11 June 2018Vienna, Austria, June 11, 2018 – Themis announced today that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to its most advanced program in development, a vaccine to prevent chikungunya fever. The PRIME scheme is designed to provide enhanced regulatory support for the development of medicines that target an unmet medical need. Chikungunya is a mosquito-transmitted disease that can have debilitating long-term effects and has no current treatment or prevention options. Themis’ vaccine candidate has shown excellent safety and immune-response data in clinical testing to date. Final results of a large dose-confirmation Phase 2 trial are expected in mid-2018. Additional Phase 2 trials are underway, totaling over 600 study volunteers in the US, EU and Central America.

The PRIME initiative was launched by EMA in 2016 to facilitate the development of medicines that target an important unmet medical need and may offer a major therapeutic advantage or benefit to patients without treatment options. These medicines are considered priority medicines within the European Union (EU). PRIME offers enhanced support to medicine developers to strengthen clinical trial designs, facilitate the generation of high-quality data and enable accelerated assessment of medicine applications.

About Themis

Themis Bioscience is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating disease with global outbreak potential. Our innovation in vaccine technology has created a powerful platform and a growing pipeline addressing a broad range of infectious diseases. Together with industrial and academic leaders we work to prevent illness across the globe. For more information, visit http://www.themisbio.com.

 

Contact For Themis:

Dr. Erich Tauber, CEO

Phone: +43 1 236 7151

[YjY0dGFnOmVyaWNoLnRhdWJlckB0aGVtaXNiaW8uY29t]

Media requests for Themis:

Gretchen Schweitzer or Dr. Stephanie May

Trophic Communications

Phone: +49 89 2388 7730 or +49 171 185 56 82

[YjY0dGFnOm1heUB0cm9waGljLmV1]

 

CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS

more

Themis Establishes Scientific Advisory Board of Experts in Virology and Vaccine Development

more

Themis Raises EUR 10 Million in Series C Financing to Advance Clinical Pipeline

more

Themis to Present Phase 2 Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting

more

Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK

more

Chikungunya-Fever: Themis Bioscience Starts Phase II Clinical Study in Endemic Area

more

NIH and Themis Bioscience Announce the Initiation of a Clinical Trial of a Chikungunya Vaccine

more

Zika Virus: Themis Bioscience Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine

more

Zika Virus: Top EU-Groups Join Forces in Quest for Vaccine. Themis Measles Vector Technology Central to Action Plan

more

Themis Bioscience Successfully Closes 10 M EUR Financing Round

more

Zika Vaccine Development Receives Big Boost by Innovate UK

more

Interview W24/Zika

more

New worldwide, exclusive license agreement provides broad access to Institut Pasteur's virus vector technology – Zika vaccine development progressing with high priority.

more

New Horizons For Measles-Based Vaccines And Therapies

more

Two renowned Vaccine Experts Joining Themis Bioscience GmbH

more

Themis Bioscience’s Raises up to EUR 10 Million in Series B New Board to drive partnerships and commercialization of product pipeline

more